[
  {
    "ts": null,
    "headline": "Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains",
    "summary": "Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=a89d91bd788aab8dc241eb92f20786c50fe5c6c88784c8a4c2bbaeb720ce669b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732207140,
      "headline": "Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains",
      "id": 131600604,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=a89d91bd788aab8dc241eb92f20786c50fe5c6c88784c8a4c2bbaeb720ce669b"
    }
  },
  {
    "ts": null,
    "headline": "Amgen and Pfizer appoint new Science executives",
    "summary": "Several new appointments were announced by Amgen and Pfizer yesterday, focusing on R&D functions.Pfizer Inc. is appointing Dr Chris Boshoff, PhD, as Chief Scientific Officer and ...",
    "url": "https://finnhub.io/api/news?id=8e8437eb422472f848ef86b34366026ab054634fb31944ee77586428709b16b9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732190474,
      "headline": "Amgen and Pfizer appoint new Science executives",
      "id": 131541217,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Several new appointments were announced by Amgen and Pfizer yesterday, focusing on R&D functions.Pfizer Inc. is appointing Dr Chris Boshoff, PhD, as Chief Scientific Officer and ...",
      "url": "https://finnhub.io/api/news?id=8e8437eb422472f848ef86b34366026ab054634fb31944ee77586428709b16b9"
    }
  },
  {
    "ts": null,
    "headline": "Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares",
    "summary": "Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might measure up against the popular GLP-1 drugs sold by Eli Lilly and Novo Nordisk.  Encouraging comments from Amgen about the 52-week Phase 2 trial helped fuel an 8% rise in the company's shares over the past year.  Amgen has said its drug could offer quicker weight loss and possibly better weight maintenance, as well as fewer shots, than once-weekly GLP-1s such as Novo's Wegovy and Lilly's Zepbound.",
    "url": "https://finnhub.io/api/news?id=97fac45553a2448b32dbf51884b62bc51d88dafb71960d5004796b3b20bc7b12",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732187654,
      "headline": "Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares",
      "id": 131543378,
      "image": "https://media.zenfs.com/en/reuters.com/3d77b6423c6c1aab8943e663f9b20ad8",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might measure up against the popular GLP-1 drugs sold by Eli Lilly and Novo Nordisk.  Encouraging comments from Amgen about the 52-week Phase 2 trial helped fuel an 8% rise in the company's shares over the past year.  Amgen has said its drug could offer quicker weight loss and possibly better weight maintenance, as well as fewer shots, than once-weekly GLP-1s such as Novo's Wegovy and Lilly's Zepbound.",
      "url": "https://finnhub.io/api/news?id=97fac45553a2448b32dbf51884b62bc51d88dafb71960d5004796b3b20bc7b12"
    }
  },
  {
    "ts": null,
    "headline": "Amgen picks prolific biotech founder Chang as new top scientist",
    "summary": "Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to overcome the looming loss of exclusivity for some of its top-selling medicines.",
    "url": "https://finnhub.io/api/news?id=69f78a446444d45ce750917ce07f14d0003eb135076f9b0bb07e60517808e5dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732182010,
      "headline": "Amgen picks prolific biotech founder Chang as new top scientist",
      "id": 131543379,
      "image": "https://imgproxy.divecdn.com/WZJwjiYg6JSUuoVpUU7JxIHND0QhsZRL-z-j1OVaKiA/g:ce/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0FtZ2VuX1Bob3RvXzEuSlBH.webp",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to overcome the looming loss of exclusivity for some of its top-selling medicines.",
      "url": "https://finnhub.io/api/news?id=69f78a446444d45ce750917ce07f14d0003eb135076f9b0bb07e60517808e5dd"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop",
    "summary": "Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come.",
    "url": "https://finnhub.io/api/news?id=dfda1926e671678dccbbb12ba7b032825f7eee768857c878c107a51f6206f74c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732172400,
      "headline": "Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop",
      "id": 131527116,
      "image": "",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come.",
      "url": "https://finnhub.io/api/news?id=dfda1926e671678dccbbb12ba7b032825f7eee768857c878c107a51f6206f74c"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street awaits Amgen weight-loss drug data expected to move shares",
    "summary": "Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might measure up against the popular GLP-1 drugs sold by Eli Lilly and Novo...",
    "url": "https://finnhub.io/api/news?id=3e2eb68cec4f62cc0e476121ec6741714473432293f1fc391f0a4527e1cc7068",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732169654,
      "headline": "Wall Street awaits Amgen weight-loss drug data expected to move shares",
      "id": 131534931,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might measure up against the popular GLP-1 drugs sold by Eli Lilly and Novo...",
      "url": "https://finnhub.io/api/news?id=3e2eb68cec4f62cc0e476121ec6741714473432293f1fc391f0a4527e1cc7068"
    }
  },
  {
    "ts": null,
    "headline": "BPCIA Lawsuit Against Accord's Proposed Prolia® / Xgeva® Biosimilar Filed By Amgen",
    "summary": "On November 13, 2024, Amgen filed Case No. 5:24-cv-00642 against Accord BioPharma and Intas Pharmaceuticals, alleging INTP23, their proposed Prolia® / Xgeva® biosimilar, would infringe 34 of...",
    "url": "https://finnhub.io/api/news?id=210e8d301191d5a97d4882338692d51a8b6e30e9b770063a60296faeb4f14a7c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732158606,
      "headline": "BPCIA Lawsuit Against Accord's Proposed Prolia® / Xgeva® Biosimilar Filed By Amgen",
      "id": 131527447,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "On November 13, 2024, Amgen filed Case No. 5:24-cv-00642 against Accord BioPharma and Intas Pharmaceuticals, alleging INTP23, their proposed Prolia® / Xgeva® biosimilar, would infringe 34 of...",
      "url": "https://finnhub.io/api/news?id=210e8d301191d5a97d4882338692d51a8b6e30e9b770063a60296faeb4f14a7c"
    }
  }
]